<DOC>
	<DOC>NCT01357239</DOC>
	<brief_summary>This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.</brief_summary>
	<brief_title>Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Patients with Fragile X Syndrome, who are at least moderately ill based on a Clinical Global Impression Severity score of at least 4 and have qualifying scores on the ABCC and IQ test at Visit 1 Advanced, severe or unstable disease that may interfere with the study outcome evaluations Cancer within the past 5 years, other than localized skin cancer Current treatment with more than two psychoactive medications, excluding antiepileptics History of severe selfinjurious behavior Weigh less than 32 kg Females who are sexually active Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Fragile X Syndrome</keyword>
	<keyword>Martin-Bell Syndrome</keyword>
	<keyword>Genetic Diseases</keyword>
	<keyword>X-Linked</keyword>
	<keyword>Escalante's syndrome</keyword>
</DOC>